compound semaglutide ban Fifth Circuit probes FDA on compounded GLP-1s Compounded Semaglutide & Tirzepatide 2025:

Off-label prescribing is a common practice physicians use to prescribe an FDA-approved drug at different doses or for reasons other than what the drug is approved to treat

Accordingly, currently ongoing trials in HF (HFpEF) with the GLP-1 RA semaglutide (2.4 mg for once-weekly subcutaneous injection, i.e., the dose approved for weight management) enrols people with obesity with (STEP-HFpEF DM trial

If your travel schedule is unpredictable, consider timing reconstitution to occur at your destination rather than before departure

Thus, oral administration of a peptide therapeutic represents a significant advance in medicine, but is challenged by gastrointestinal instability and ineffective uptake into the circulation

At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC

This Week in GLP-1: A $149 Pill, Wegovy HD, and Canadian Generic Delays Here's what happened this week in GLP-1 medications and every story matters if you're waiting for more affordable options in Canada